Clinical Trial Update: Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

This Phase 2 neoadjuvant trial evaluates Visugromab, an anti-GDF-15 antibody, in combination with immunotherapy for muscle-invasive bladder cancer. The study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Bladder Cancer

Drugs mentioned

• Visugromab (Visugromab)

Snippet

Sponsor: CatalYm GmbH | Conditions: Bladder Cancer, Adult Solid Tumor | Phase 2 | Status: ACTIVE_NOT_RECRUITING